Artificial pancreas systems in diabetes: Types, benefits, challenges and limitations

Kohta Thierriy*

Received: 18-Oct-2024, Manuscript No. FMDM-24-157425; **Editor assigned:** 21-Oct-2024, PreQC No. FMDM-24-157425 (PQ); **Reviewed:** 05-Nov-2024, QC No. FMDM-24-157425; **Revised:** 12-Nov-2024, Manuscript No. FMDM-24-157425 (R); **Published:** 19-Nov-2024, DOI: 10.37532/1758-1907.2024.14(6).671-672.

Description

Diabetes management has undergone significant advancements over the years, moving from manual insulin injections and frequent blood glucose monitoring to more sophisticated technologies. One of the most promising innovations is the artificial pancreas system, which aims to mimic the function of a healthy pancreas by automatically regulating blood glucose levels. This system has the potential to significantly improve the quality of life for individuals with Type 1 and Type 2 diabetes.

■ Artificial pancreas system

An Artificial Pancreas System (APS), also known as a closed-loop insulin delivery system, is a technological innovation designed to automate the regulation of blood glucose levels in people with diabetes. It combines three key components:

Continuous Glucose Monitor (CGM): A small sensor worn on the body that continuously measures blood glucose levels, typically every 1-5 minutes. The CGM transmits real-time glucose readings to the system.

Insulin pump: A device that delivers insulin into the body through a catheter or needle. The insulin pump is programmed to release insulin based on the user's needs, such as a basal (background) insulin dose and boluses (extra insulin for meals or corrections).

Algorithm: The software that connects the CGM and insulin pump. It uses real-time glucose data to adjust insulin delivery automatically, ensuring blood glucose levels stay within a target range. The algorithm continuously evaluates the data from the CGM and determines whether more insulin is needed to lower blood glucose levels or whether insulin should be reduced or paused to prevent hypoglycemia.

■ Types of artificial pancreas systems

There are three main types of artificial pancreas systems, each with varying levels of automation:

Hybrid closed-loop system: This is the most common and widely available type of artificial pancreas system. It combines automated insulin delivery with manual bolus injections for meals. The user enters information about their meal or insulin correction dose, but the system handles the majority of insulin adjustments.

Fully closed-loop system: This system aims to be fully automated, with the CGM and insulin pump working together to adjust insulin delivery without any user input. It responds to both meal-related glucose changes and basal insulin needs, reducing the need for manual adjustments.

Open-loop system with automated insulin delivery: In this system, the insulin pump delivers insulin based on pre-programmed settings but does not rely on real-time glucose feedback from the CGM. Some advanced systems can be upgraded to include automated insulin delivery based on CGM readings.

■ Benefits of artificial pancreas systems

Improved blood glucose control: One of the most significant benefits of artificial pancreas systems is their ability to maintain blood glucose levels within a narrow target range, reducing the risk of both hyperglycemia and hypoglycemia.

Department of Medicine, Hosei University, Tokyo, Japan
**Author for correspondence: E-mail: Kohtathierriy@gmail.com*

Reduced risk of hypoglycemia: By continuously adjusting insulin delivery based on real-time glucose data, artificial pancreas systems help reduce the risk of dangerous low blood sugar levels (hypoglycemia), which is a major concern for people with diabetes using traditional insulin therapy.

Convenience: The automation of insulin delivery makes it easier for people with diabetes to manage their condition. Individuals do not need to manually adjust insulin doses throughout the day, allowing them to focus on other aspects of life without constant worry about blood sugar levels.

Improved quality of life: Many users report better overall quality of life with artificial pancreas systems due to reduced daily burdens associated with managing diabetes. They also experience less anxiety about blood sugar fluctuations, especially during sleep.

Better sleep: Since the artificial pancreas continuously adjusts insulin delivery throughout the night, users can sleep more soundly, knowing their blood sugar is being monitored and controlled.

■ Challenges and limitations

While artificial pancreas systems offer significant benefits, there are also several challenges and limitations to consider:

Cost and accessibility: One of the biggest barriers to widespread use is the cost of these systems. The price of CGMs, insulin pumps, and the necessary technology can be prohibitive for some people, particularly in regions with limited access to healthcare. Insurance coverage for these devices also varies, which can limit access to those who need it most.

Technical issues: Like any technology, artificial pancreas systems can experience malfunctions or glitches. For example, sensor errors, signal loss between the CGM and insulin pump, or inaccurate glucose readings can lead to incorrect insulin delivery, which could put the user at risk.

User training: While the systems are designed to be user-friendly, individuals still need to understand how to use them effectively. Proper training on how to set up, maintain, and troubleshoot the system is essential to ensure safety and optimal performance.

Regulatory approvals: Fully closed-loop systems are still in the process of gaining regulatory approval in many countries. Although hybrid closed-loop systems are available, further research and development are needed to bring fully automated systems to market.

Sensor accuracy: The accuracy of the CGM plays a crucial role in the effectiveness of the artificial pancreas. Inaccurate glucose readings can lead to inappropriate insulin delivery, potentially causing hypoglycemia or hyperglycemia.